Treatment decisions for BC are mainly based on clinicopathological variables that are prognostic, such as tumor size, presence of lymph node metastasis, grading, and three predictive markers (ER, PR and HER2). Here, ESR1 is linked to metastatic malignant neoplasm in the lymph nodes.